Table 2.

Different criteria for HPD from clinical perspective [adapted from Table from the paper of Hongjing et al. (174)].

Name	Cancer types	Applications	Criteria	Advantages	Disadvantages	Reference
TGRR	Solid tumours	PD-1/PD-L1 inhibitors	TGRR ≥2	First HPD definition	Pre-ICI treatments details are needed	(175)
TGKR	R/M HNSCC	PD-1/PD-L1 inhibitors	TGKR ≥2	Pseudoprogression and HPD can be distinguished	Pre-ICI treatments details are needed	(176)
Kato et al. criteria	Multiple types of solid tumours	Immunotherapy agents	TTF < 2 months; 50% increase in tumour burden; >2-fold change in progression rate	Need less time for HPD characteristics	Clinical status changes are ignored	(11)
Lo Russo et al. criteria	Multiple types of solid tumours	ICIs	TTF < 2 months; 50% increase in tumour lesions; ≥ 2 new lesions; spread of disease; clinical deterioration by ECOG	Applicable for first-line treatment with ICIs	Higher false positive rate	(12)